Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 6Lung Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumor 4Multiple Myeloma 4Prostatic Neoplasms 3Ovarian Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Solitary Fibrous Tumors 1

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Lung Neuroendocrine Tumor × Fluorodeoxyglucose F18 × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡